Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: Curis is engaged in the discovery of drug targets and development of therapeutics based on tissue repair pathways, focusing on kidney disease, cancer, and neurological disorders. The company recently executed a "Realignment" strategy to reduce costs and refocus on proprietary signaling pathways (BMP and Hedgehog) and stem cell technologies.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 |
|---|---|---|
| Total Revenues | $222,351 | $570,676 |
| Net Loss | $(5,752,685) | $(94,566,323) |
| Net Loss Applicable to Common Stockholders | $(5,932,910) | $(95,109,001) |
| Net Loss Per Share (Basic & Diluted) | $(0.18) | $(2.92) |
| Cash and Cash Equivalents (End of Period) | $12,148,890 | $12,148,890 |
| Total Debt (Current + Long-Term) | $6,106,365 | $6,106,365 |
| Convertible Notes Payable | $5,778,985 | $5,778,985 |
| Net Cash Used in Operating Activities | N/A | $(19,101,003) |
Note: Total Debt includes current portion of debt/leases ($2,052,740), long-term debt/leases ($4,053,625), and convertible notes ($5,778,985).
Material Changes vs. Prior Period
- Revenue: Total revenues decreased 23% to $222,000 for the quarter and 23% to $571,000 for the nine-month period compared to 2001. This decline is attributed to the cessation of NIST grant revenues in 2002, partially offset by royalty revenue from Stryker.
- Operating Expenses: Research and development expenses decreased 58% ($4.0M) for the quarter and 49% ($11.3M) for the nine-month period due to the Realignment program, workforce reductions, and facility closures.
- Impairment Charges: The nine-month period included a significant non-cash goodwill impairment charge of $64,098,345 and a property and equipment impairment charge of $5,336,785. These charges were driven by a decline in market capitalization and the Realignment strategy.
- Joint Venture Loss: Equity in loss of joint venture (Curis Newco) decreased 92% to $977,000 for the quarter and 75% to $3,217,000 for the nine-month period, primarily due to a one-time $15M technology write-off recorded by the joint venture in 2001.
- Amortization: Amortization of intangible assets dropped 99% due to the adoption of SFAS No. 142, which ceased the amortization of goodwill.
Guidance, Outlook, and Risks
- Subsequent Event (Stryker Transaction): On October 1, 2002, Curis completed a transaction with Stryker Corporation receiving $14,000,000 in cash in exchange for terminating future BMP-7 royalty obligations. This amount is expected to be recorded as revenue in the fourth quarter of 2002.
- Liquidity Outlook: Management anticipates that existing capital resources, including the $14M Stryker payment and borrowings under a note agreement with Elan Pharma International, Ltd. (EPIL), will fund operations into the second quarter of 2004.
- Financing Needs: The company expects to incur substantial additional R&D costs. Future funding beyond mid-2004 depends on collaboration success and the ability to raise additional equity or debt capital.
- Listing Risk: The company received a deficiency notice from NASDAQ regarding failure to maintain a minimum bid price of $1.00. Compliance must be regained by November 29, 2002, or the stock faces delisting from the NASDAQ National Market.
- Joint Venture Funding: Funding for the Curis Newco joint venture is contingent upon EPIL's consent for drawdowns under a convertible promissory note.
Investor Verification Checklist
- Stryker Revenue Recognition: Verify the timing and accounting treatment of the $14M Stryker payment expected in Q4 2002.
- Goodwill Impairment Methodology: Review the assumptions used in the SFAS 142 impairment test, specifically the control premium and discounted cash flow estimates for in-process technology.
- NASDAQ Compliance: Monitor the company's ability to regain compliance with NASDAQ listing requirements by the November 29, 2002 deadline.
- Debt Covenants and Convertible Notes: Assess the terms of the $5.8M convertible notes payable and the $4.7M term loan with Boston Private Bank, including interest rates and collateral requirements.
- Joint Venture Dependency: Evaluate the risk associated with the Curis Newco joint venture, specifically the reliance on EPIL consent for funding drawdowns.